Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Trial Profile

Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Registrational
  • Acronyms TIMO
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 25 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jan 2016 Planned End Date changed from 1 Sep 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 27 Jan 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top